The initial appetite suppression is often the first sign your body is responding to the medication, even before measurable weight changes occur
Additionally, IRF3 inhibits the nuclear translocation of -catenin translocation, thereby inhibiting CRC cell growth (Tian et al., 2020)
Your individual potential depends on starting weight, genetics, and medication responsiveness
A physician may first review side effects, nutrition, hydration, constipation, protein intake, activity, current dose, medication consistency, and lab markers
Yes, you can travel with compounded semaglutide
Rebound fat gain is a concern users raise frequently, but the evidence doesn't support it as a direct peptide cessation effect